I-5022 Ixabepilone, Free Base, >99%

Synonyms : [Azaepothilone B] [BMS-247550] [BMS 247550-1]

Related Terms : [Ixempra]

  • Size
  • US $
  • £
  • ¥
  • 1 mg
  • 129
  • 114
  • 96
  • 14,600
  • Add to Cart Qty:
  • In stock
  • 5 mg
  • 315
  • 278
  • 235
  • 35,700
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 492
  • 434
  • 368
  • 55,800
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 995
  • 879
  • 745
  • 112,800
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 506.70
  • C27H42N2O5S
  • [219989-84-1]
  • M.I. 15: 5297

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 90 mg/mL. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • Ixabepilone, also known as BMS-247550, is an epothilone B analog and microtubule-stabilizing agent. Ixabepilone showed potent induction of tubulin polymerization, with an EC0.01 value of 3.5 µM (about 2-fold lower than paclitaxel, please see Cat. No. P-9600, Paclitaxel). Ixabepilone showed activity against 21 paclitaxel-sensitive and paclitaxel-resistant cell lines with IC50 values of 1.4 - 34.5 nM and retained its antineoplastic activity against human cancers that were naturally insensitive to paclitaxel or that had developed resistance to paclitaxel in vivo. Lee, F.Y., et al. "BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy." Clin. Cancer Res. 7: 1429-1437 (2001).
  • Ixabepilone demonstrated superior preclinical characteristics, including high metabolic stability, low plasma protein binding (79.4%) and low susceptibility to multidrug resistance protein-mediated efflux. Lee, F.Y., et al. "Preclinical discovery of ixabepilone, a highly active antineoplastic agent." Cancer Chemother. Pharmacol. 63: 157-166 (2008).
  • Combined treatment with ixabepilone and capecitabine (please see Cat. No. C-2799, Capecitabine) in an international phase 3 study demonstrated superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated with or resistant to anthracyclines and resistant to taxanes. Thomas, E.S., et al. "Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment." J. Clin. Oncol. 25: 5210-5217 (2007).
  • Ixabepilone is the active ingredient in the drug product sold under the trade name Ixempra®. This drug is currently approved in at least one country for use in patients with aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. NOTE: THE IXABEPILONE SOLD BY LC LABORATORIES FOR RESEARCH IS NOT IXEMPRA®, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.